BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1035 related articles for article (PubMed ID: 32467995)

  • 101. Clustered Regularly Interspaced Short Palindromic Repeats System of Genome Engineering in Embryos to Repair Genes.
    Niazvand F; Fathinezhad Z; Alfuraiji N; Etajuri EA; Amini-Chermahini F; Chehelgerdi M; Ranjbar R
    J Biomed Nanotechnol; 2021 Mar; 17(3):331-356. PubMed ID: 33875070
    [TBL] [Abstract][Full Text] [Related]  

  • 102. CRISPR Cas System: An efficient tool for cancer modelling.
    Akhtar M; Jamal T; Khan M; Khan SR; Haider S; Jalil F
    J Pak Med Assoc; 2021 Feb; 71(2(B)):718-724. PubMed ID: 33941966
    [TBL] [Abstract][Full Text] [Related]  

  • 103. CRISPR base editing applications for identifying cancer-driving mutations.
    Pal M; Herold MJ
    Biochem Soc Trans; 2021 Feb; 49(1):269-280. PubMed ID: 33449100
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
    Wan T; Ping Y
    Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
    [TBL] [Abstract][Full Text] [Related]  

  • 105. More specific CRISPR editing.
    de Souza N
    Nat Methods; 2014 Jul; 11(7):712. PubMed ID: 25110782
    [No Abstract]   [Full Text] [Related]  

  • 106. CRISPR/Cas9 system: a reliable and facile genome editing tool in modern biology.
    Javaid D; Ganie SY; Hajam YA; Reshi MS
    Mol Biol Rep; 2022 Dec; 49(12):12133-12150. PubMed ID: 36030476
    [TBL] [Abstract][Full Text] [Related]  

  • 107. CRISPR technologies for genome, epigenome and transcriptome editing.
    Villiger L; Joung J; Koblan L; Weissman J; Abudayyeh OO; Gootenberg JS
    Nat Rev Mol Cell Biol; 2024 Jun; 25(6):464-487. PubMed ID: 38308006
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease.
    Baker C; Hayden MS
    F1000Res; 2020; 9():281. PubMed ID: 32528662
    [TBL] [Abstract][Full Text] [Related]  

  • 109. An engineered ScCas9 with broad PAM range and high specificity and activity.
    Chatterjee P; Jakimo N; Lee J; Amrani N; Rodríguez T; Koseki SRT; Tysinger E; Qing R; Hao S; Sontheimer EJ; Jacobson J
    Nat Biotechnol; 2020 Oct; 38(10):1154-1158. PubMed ID: 32393822
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease.
    Mehmood A; Ali W; Din ZU; Song S; Sohail M; Shah W; Guo J; Guo RY; Ilahi I; Shah S; Al-Shaebi F; Zeb L; Asiamah EA; Al-Dhamin Z; Bilal H; Li B
    Brain Behav; 2021 Aug; 11(8):e2280. PubMed ID: 34291612
    [TBL] [Abstract][Full Text] [Related]  

  • 111. CRISPR therapy towards an HIV cure.
    Herrera-Carrillo E; Gao Z; Berkhout B
    Brief Funct Genomics; 2020 May; 19(3):201-208. PubMed ID: 31711197
    [TBL] [Abstract][Full Text] [Related]  

  • 112. CRISPR-mediated genome editing in non-conventional yeasts for biotechnological applications.
    Cai P; Gao J; Zhou Y
    Microb Cell Fact; 2019 Apr; 18(1):63. PubMed ID: 30940138
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Assessing Off-Target Editing of CRISPR-Cas9 Systems.
    Pruett-Miller SM
    CRISPR J; 2020 Dec; 3(6):430-432. PubMed ID: 33346715
    [No Abstract]   [Full Text] [Related]  

  • 114. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
    Jacinto FV; Link W; Ferreira BI
    J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Insights of CRISPR-Cas systems in stem cells: progress in regenerative medicine.
    Dilip Kumar S; Aashabharathi M; KarthigaDevi G; Subbaiya R; Saravanan M
    Mol Biol Rep; 2022 Jan; 49(1):657-673. PubMed ID: 34687393
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Recent Advances in CRISPR/Cas9 Delivery Strategies.
    Yip BH
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Therapeutic genome editing in cardiovascular diseases.
    Nishiga M; Qi LS; Wu JC
    Adv Drug Deliv Rev; 2021 Jan; 168():147-157. PubMed ID: 32092381
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Harnessing CRISPR-Cas for oomycete genome editing.
    Vink JNA; Hayhurst M; Gerth ML
    Trends Microbiol; 2023 Sep; 31(9):947-958. PubMed ID: 37127441
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease.
    Schrauben M; Dempster E; Lunnon K
    Brain Pathol; 2020 Sep; 30(5):992-1004. PubMed ID: 32654206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.